Lee DH, et al. - In Koreans with diabetes and subclinical coronary atherosclerosis, researchers assessed the impact of cilostazol (CTZ), a phosphodiesterase-3 inhibitor, vs aspirin (acetylsalicylic acid; ASA). In this single-center, prospective randomized open-blind endpoint study, 100 people with diabetes who suffered from mild to moderate coronary atherosclerosis were randomly allocated to either 200 mg/d CTZ or 100 mg/d ASA (n = 50 each group). Investigators found that 12 months of CTZ treatment reduced coronary artery stenosis (5.3% difference vs ASA) and the non-calcified plaque element (4.7 mm³ difference vs aspirin). CTZ treatment might be a good choice for people with diabetes who need to stop coronary atherosclerosis from progressing.